pharmaphorum

Alnylam's ATTR cardiomyopathy drug backed for NHS use

Patients in England and Wales with cardiomyopathy caused by the disorder ATTR amyloidosis will soon be able to access treatment with Alnylam's gene-silencing drug Amvuttra. The ruling by reimbursement ...
Ecommerce Fastlane

What Is an Iframe? Pros, Cons, and How To Embed Them

Visitors to your website might want directions to your store via Google Maps, a roundup of your social media feeds, and a ...
findnerd.com

jQuery .prop() vs .attr()

Get the value of an attribute for the first element in the set of matched elements. An attribute value may only be a string. The attributes contains basic information ...
FiercePharma

Pfizer reported an ATTR sales decline in the US. Should newer market entrants Alnylam and BridgeBio worry?

The burgeoning field of transthyretin amyloid cardiomyopathy (ATTR-CM), which spurred excitement over a potential $20 billion market, may have just revealed the first indication of a slowdown. For the ...
Health.com

4 Ways Doctors Can Detect ATTR-CM, a Rare and Difficult-To-Diagnose Heart Condition

Alexandria Nyembwe is a registered nurse and health writer. She has worked in street medicine serving populations experiencing homelessness in Skid Row Los Angeles as well as in cardiovascular care in ...
PharmaTimes

NICE recommends vutrisiran for adults with ATTR-CM in final draft guidance

First long-acting therapy with three-monthly dosing to target root cause of cardiac disease The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending ...
Medscape

NICE Endorses Vutrisiran for ATTR-CM Treatment

The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending vutrisiran for patients with wild-type and hereditary transthyretin amyloidosis with ...
Seeking Alpha

Intellia: Moving To 'Hold' Rating In Light Of Nex-Z Uncertainty In ATTR Patients (Downgrade)

The last time I spoke about Intellia Therapeutics (NTLA), it was with a Seeking Alpha article entitled "Nex-Z Advancement Remains On Track With Expanded ATTRv-PN Indication" With respect to this ...
Seeking Alpha

Alnylam raises 2025 revenue guidance to $3.05B amid robust AMVUTTRA ATTR-CM launch momentum

CEO Yvonne Greenstreet highlighted that "Alnylam's Q3 results announced this morning demonstrate the exceptional progress we are making across all aspects of the business." Greenstreet stated, "Our ...
Healthline

What to Know About Transthyretin Amyloidosis (ATTR) Genetic Testing

Genetic testing for ATTR can detect transthyretin mutations and offer crucial information about risk, monitoring, and treatment, if needed. Transthyretin amyloidosis (ATTR) is a genetic condition that ...
The New England Journal of Medicine

Nexiguran Ziclumeran Gene Editing in Hereditary ATTR with Polyneuropathy

Hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN) is a rare, multisystem, progressive, debilitating, and fatal disease characterized by tissue deposition of misfolded transthyretin ...